Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP-700 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABP-700 30 μg/kg/min | EXPERIMENTAL | Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| ABP-700 40 μg/kg/min | EXPERIMENTAL | Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| ABP-700 45 μg/kg/min | EXPERIMENTAL | Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| Name | Type | Description |
|---|---|---|
| ABP-700 | DRUG | - |
Inclusion Criteria: * Participant must be male or female 18 to 75 years of age, inclusive * Participant must give written informed consent before initiation of any study-related procedures * Participant is scheduled to undergo elective colonoscopy * Body Mass Index (BMI) 18.0 to 29.0 kilogram per m...
ABP-700 is an investigational small molecule being studied for procedural sedation in adult patients undergoing colonoscopy. It is being developed by Novartis AG (NYSE: NVS). The drug is currently in Phase 2 clinical development and is not approved by the FDA.
ABP-700 is being developed by Novartis AG, a pharmaceutical company traded on the NYSE under the ticker NVS. The drug is an investigational small molecule in Phase 2 clinical development for procedural sedation during colonoscopy procedures.
ABP-700 is in Phase 2 clinical development. It is an investigational drug being studied for procedural sedation in adult patients undergoing colonoscopy. The drug is not FDA approved and remains under clinical investigation.
ABP-700 has one completed Phase 2 clinical trial, identified as NCT02800590. This study investigated the safety and efficacy of three dosing regimens of ABP-700 for procedural sedation in adult participants undergoing colonoscopy. The trial enrolled 150 participants and was conducted in the Netherlands.
ABP-700 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by Novartis AG for procedural sedation in colonoscopy.